Cargando…

Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial

BACKGROUND: Alcohol use disorder is a chronic disorder with a high likelihood of relapse. The consistent monitoring of blood alcohol concentration through breathalyzers is critical to identifying relapse or misuse. Smartphone apps as a replacement of or in conjunction with breathalyzers have shown l...

Descripción completa

Detalles Bibliográficos
Autores principales: Buono, Frank D, Gleed, Colette, Boldin, Martin, Aviles, Allison, Wheeler, Natalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800086/
https://www.ncbi.nlm.nih.gov/pubmed/35029534
http://dx.doi.org/10.2196/30186
_version_ 1784642187893407744
author Buono, Frank D
Gleed, Colette
Boldin, Martin
Aviles, Allison
Wheeler, Natalie
author_facet Buono, Frank D
Gleed, Colette
Boldin, Martin
Aviles, Allison
Wheeler, Natalie
author_sort Buono, Frank D
collection PubMed
description BACKGROUND: Alcohol use disorder is a chronic disorder with a high likelihood of relapse. The consistent monitoring of blood alcohol concentration through breathalyzers is critical to identifying relapse or misuse. Smartphone apps as a replacement of or in conjunction with breathalyzers have shown limited effectiveness. Yet, there has been little research that has effectively utilized wireless or Wi-Fi–enabled breathalyzers that can accurately, securely, and reliably measure blood alcohol concentration. OBJECTIVE: The purpose of this study is to evaluate the impact of a wireless blood alcohol concentration device in collaboration with long-term treatment on dropout rates, psychological distress, treatment motivation, quality of life, and need for higher levels of follow-up care for patients with alcohol use disorder. METHODS: The randomized clinical trial will include two arms, access to the wireless breathalyzer versus no access to the breathalyzer, while both groups have access to treatment. Evaluation will last 3 months with a 6-week follow-up, during which each participant will be interviewed at admission, 1 month in, 2 months in, 3 months in, and follow-up. Individuals will be recruited online through a secure telehealth meeting invitation. Outcomes will focus on the impact of the wireless breathalyzer within the alcohol use disorder population, and the combined effect on psychological distress, treatment motivation, and quality of life. In addition, we intend to investigate the impact of the breathalyzer on dropout rates and participants’ need for higher levels of follow-up care and treatment. RESULTS: The recruitment of this study started in July 2020 and will run until 2022. CONCLUSIONS: This information will be important to develop cost-effective treatments for alcohol dependence. Ongoing monitoring allows treatment providers to take an individualized disease management approach and facilitates timely intervention by the treatment provider. TRIAL REGISTRATION: ClinicalTrials.gov NCT04380116; http://clinicaltrials.gov/ct2/show/NCT04380116 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/30186
format Online
Article
Text
id pubmed-8800086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-88000862022-02-03 Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial Buono, Frank D Gleed, Colette Boldin, Martin Aviles, Allison Wheeler, Natalie JMIR Res Protoc Protocol BACKGROUND: Alcohol use disorder is a chronic disorder with a high likelihood of relapse. The consistent monitoring of blood alcohol concentration through breathalyzers is critical to identifying relapse or misuse. Smartphone apps as a replacement of or in conjunction with breathalyzers have shown limited effectiveness. Yet, there has been little research that has effectively utilized wireless or Wi-Fi–enabled breathalyzers that can accurately, securely, and reliably measure blood alcohol concentration. OBJECTIVE: The purpose of this study is to evaluate the impact of a wireless blood alcohol concentration device in collaboration with long-term treatment on dropout rates, psychological distress, treatment motivation, quality of life, and need for higher levels of follow-up care for patients with alcohol use disorder. METHODS: The randomized clinical trial will include two arms, access to the wireless breathalyzer versus no access to the breathalyzer, while both groups have access to treatment. Evaluation will last 3 months with a 6-week follow-up, during which each participant will be interviewed at admission, 1 month in, 2 months in, 3 months in, and follow-up. Individuals will be recruited online through a secure telehealth meeting invitation. Outcomes will focus on the impact of the wireless breathalyzer within the alcohol use disorder population, and the combined effect on psychological distress, treatment motivation, and quality of life. In addition, we intend to investigate the impact of the breathalyzer on dropout rates and participants’ need for higher levels of follow-up care and treatment. RESULTS: The recruitment of this study started in July 2020 and will run until 2022. CONCLUSIONS: This information will be important to develop cost-effective treatments for alcohol dependence. Ongoing monitoring allows treatment providers to take an individualized disease management approach and facilitates timely intervention by the treatment provider. TRIAL REGISTRATION: ClinicalTrials.gov NCT04380116; http://clinicaltrials.gov/ct2/show/NCT04380116 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/30186 JMIR Publications 2022-01-14 /pmc/articles/PMC8800086/ /pubmed/35029534 http://dx.doi.org/10.2196/30186 Text en ©Frank D Buono, Colette Gleed, Martin Boldin, Allison Aviles, Natalie Wheeler. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 14.01.2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Buono, Frank D
Gleed, Colette
Boldin, Martin
Aviles, Allison
Wheeler, Natalie
Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
title Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
title_full Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
title_fullStr Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
title_full_unstemmed Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
title_short Preliminary Effectiveness of a Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality: Protocol for a Randomized Controlled Trial
title_sort preliminary effectiveness of a remotely monitored blood alcohol concentration device as treatment modality: protocol for a randomized controlled trial
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800086/
https://www.ncbi.nlm.nih.gov/pubmed/35029534
http://dx.doi.org/10.2196/30186
work_keys_str_mv AT buonofrankd preliminaryeffectivenessofaremotelymonitoredbloodalcoholconcentrationdeviceastreatmentmodalityprotocolforarandomizedcontrolledtrial
AT gleedcolette preliminaryeffectivenessofaremotelymonitoredbloodalcoholconcentrationdeviceastreatmentmodalityprotocolforarandomizedcontrolledtrial
AT boldinmartin preliminaryeffectivenessofaremotelymonitoredbloodalcoholconcentrationdeviceastreatmentmodalityprotocolforarandomizedcontrolledtrial
AT avilesallison preliminaryeffectivenessofaremotelymonitoredbloodalcoholconcentrationdeviceastreatmentmodalityprotocolforarandomizedcontrolledtrial
AT wheelernatalie preliminaryeffectivenessofaremotelymonitoredbloodalcoholconcentrationdeviceastreatmentmodalityprotocolforarandomizedcontrolledtrial